Alkermes plc
ALKS
Rangering i aksjer
#2684
Alkermes plc, a biopharmaceutical company, engages in the research,... Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Aksjekurs
$42.24
Markedsverdi
$7.09B
Endring (1 dag)
2.47%
Endring (1 år)
39.59%
Land
IE
Handel Alkermes plc (ALKS)
Kategori
Healthcare
Inntekter for Alkermes plc (ALKS)
Inntekter i Jun 2026 TTM: $97.32M
Ifølge Alkermes plc sine nyeste økonomiske rapporter er selskapets nåværende resultat $97.32M. I 2023 hadde selskapet et resultat på $421.52M, en økning sammenlignet med resultatet i 2022, som var $-31.13M. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Alkermes plc fra 2000 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $97.32M | -78.07% |
| 2024 | $443.75M | 5.27% |
| 2023 | $421.52M | -1,454.15% |
| 2022 | $-31.13M | -135.48% |
| 2021 | $87.73M | -190.87% |
| 2020 | $-96.54M | -51.01% |
| 2019 | $-197.06M | 55.20% |
| 2018 | $-126.97M | -11.38% |
| 2017 | $-143.27M | -33.17% |
| 2016 | $-214.39M | -4.29% |
| 2015 | $-224.01M | 1,496.73% |
| 2014 | $-14.03M | -139.58% |
| 2013 | $35.44M | 0.00% |
| 2012 | $35.44M | -130.98% |
| 2011 | $-114.39M | 146.05% |
| 2010 | $-46.49M | 4.00% |
| 2009 | $-44.70M | -134.12% |
| 2008 | $131.01M | -24.20% |
| 2007 | $172.83M | 1,539.29% |
| 2006 | $10.54M | 0.00% |
| 2005 | 0.00 | -100.00% |
| 2004 | $-75.17M | 0.00% |
| 2003 | 0.00 | -100.00% |
| 2002 | $-106.90M | 74.23% |
| 2001 | $-61.35M | 263.71% |
| 2000 | $-16.87M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $5.27B | 5,320.16% |
US
|
|
| $-3.09B | -3,272.01% |
US
|
|
| $-4.02B | -4,226.79% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 1,904.37% |
NL
|
